Radiopharm Theranostics reports positive Phase 1 imaging data for RAD301
Radiopharm Theranostics said its Phase 1 imaging trial of RAD301 in pancreatic ductal adenocarcinoma showed positive safety and favourable biodistribution in all dosed subjects, with significant tumour uptake in all evaluable patients.
Positive safety and favourable biodistribution were seen in all subjects dosed. Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake. The data support RAD301’s targeting potential and its continued clinical development. SYDNEY, Australia, Sept.
09, 2026 (GLOBE…